844.CKD.ESRD (844.253.3773) | Frenova.com Case Study: Vifor A Pivotal Phase III Study for FDA Approval of Velphoro® (Sucroferric Oxyhydroxide), a Hyperphosphatemia Medication Background Client: Vifor Pharma (the pharmaceutical business arm of the Galenica Group) Project: Phase III clinical study of Velphoro Scope: Multicenter global trial Sites: 174 globally, 65 in the U.S. Patients: 1,000+ globally, 500+ in the U.S. Hyperphosphatemia, an abnormal elevation of phosphorus levels in the blood, is a common and serious condition in chronic kidney disease (CKD) patients undergoing dialysis treatment. Despite dietary restriction, dialysis treatment and the availability of a number of different phosphate binders to treat this condition, up to 50 percent of patients (depending on the co

Join for free to read